This site is intended for U.S. health care professionals.
- Pfizer Products
- Support & Services
- Clinical Trial Listings
- Digital Product Presentations
- Get Healthy Stay Healthy
- Grants & Fellowships
- Hispanic/Latino Learning Series
- Patient Assistance Programs
- Pfizer Medical Information
- Pfizer Patient-Reported Outcomes
- Pfizer Responsible Disposal Advisor Site
- Pfizer Samples
- Speaker Portal
- Vaccine Ordering
- Sign In/Register
- Pfizer Samples Sign In/Register
ACIP PUBLISHES RECOMMENDATIONS FOR SEROGROUP B MENINGOCOCCAL (MenB) DISEASE VACCINATION IN ADOLESCENTS AND YOUNG ADULTS.1
MenB VACCINATION MAY BE ADMINISTERED TO ALL INDIVIDUALS BETWEEN THE AGES OF 16 THROUGH 23.1
Advisory Committee on Immunization Practices (ACIP) recommends that a MenB vaccine series may be administered to adolescents and young adults aged 16 through 23 years to provide short-term protection against most strains of MenB disease. The preferred age for MenB vaccination is 16 through 18 years.
The decision to vaccinate should be made at the individual level by healthcare providers.
CLICK HERE* TO LEARN ABOUT PREVIOUSLY PUBLISHED ACIP RECOMMENDATIONS FOR CERTAIN PERSONS AT INCREASED RISK FOR MenB DISEASE.
The Affordable Care Act ensures insurance coverage for all ACIP-recommended vaccinations. Healthcare providers should contact their individual plan to determine specific coverage and reimbursement requirements and adoption timeframes.2
MenB vaccines are available through the Vaccines for Children program.3
IMPORTANT SAFETY INFORMATION
- Severe allergic reaction after a previous dose of Trumenba is a contraindication
- Individuals with altered immunocompetence may have reduced immune responses to Trumenba
- In clinical studies, the most common solicited adverse reactions were pain at the injection site (≥85%), fatigue (≥40%), headache (≥35%), muscle pain (≥30%), and chills (≥15%)
- Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
- Safety and effectiveness has not been established in pregnant women
- Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
- Approval of Trumenba is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strains representative of prevalent strains in the United States. The effectiveness of Trumenba against diverse serogroup B strains has not been confirmed
References:1. Centers for Disease Control and Prevention. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41);1171-6. 2. The Center for Consumer Information & Insurance Oversight. Affordable Care Act Implementation FAQs - Set 12. CMS.gov Web site. http://www.cms.gov /CCIIO/Resources/Fact-Sheets-and-FAQs/aca_implementation_faqs12.html. Accessed July 23, 2015. 3. Centers for Disease Control and Prevention. Vaccines for Children Resolution No. 6/15-1. Vaccines to Prevent Meningococcal Disease. Atlanta, GA: Centers for Disease Control and Prevention; June 24, 2015.
- © 2015 Pfizer Inc.
- All rights reserved.
- December 2015